Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152253 · ClinicalTrials.gov registry record · NA
Individually Tailored and Integrated Social Support Network for Tobacco Cessation
A NA study, sponsored by The Miriam Hospital.
- Completed
- Registry status
- NA
- Development phase
- 284
- Enrollment target
NCT03152253: Completed NA study, sponsored by The Miriam Hospital.
NCT03152253 is a NA study that has completed, run by The Miriam Hospital. The registered enrollment target is 284 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03152253, a NA study, has completed, sponsored by The Miriam Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 284 participants
- Enrollment target
Study Summary
This study will continue development of a quit smoking program delivered through text messaging. Upon completion of programming we will enroll 280 participants and randomize them to a control condition or the intervention condition. Assessments will occur at enrollment, and both 3 and 6 month follow ups.
Primary Outcome
Self-report of no smoking for the past 7 days
Interventions
- BEHAVIORAL Peer Support
- OTHER Motivational Messages
- BEHAVIORAL Text My Quit (TMQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-11-30 |
| Phase | NA |
What the finished NCT03152253 record still lists
NCT03152253 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 3 interventions - of which Peer Support is the first listed.
NCT03152253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03152253 about?
NCT03152253 is a clinical study titled "Individually Tailored and Integrated Social Support Network for Tobacco Cessation". This study will continue development of a quit smoking program delivered through text messaging. Upon completion of programming we will enroll 280 participants and randomize them to a control condition or the intervention condition. Assessments will occur at enrollment, and both 3 and 6 month follow...
What is the current status of trial NCT03152253?
This trial is currently completed. It is a NA study. The enrollment target is 284 participants. The study started on 2017-05-30. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03152253?
The interventions under investigation include: Peer Support (BEHAVIORAL), Motivational Messages (OTHER), Text My Quit (TMQ) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03152253?
This trial is sponsored by The Miriam Hospital, which has 136 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03152253's enrollment target sits among peer trials
284 377th of 2000 higher than 1,623 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI